Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence is growing that low-dose aspirin used as an adjuvant treatment of cancer is associated with an increased survival and a reduction in metastatic spread. We therefore extended up to August 2017 an earlier systematic search and meta-analyses of published studies of low-dose aspirin taken by patients with a diagnosis of cancer. METHODS: Searches were completed in Medline and Embase to August 2017 using a pre-defined search strategy to identify reports of relevant studies. References in all the selected papers were scanned. Two reviewers independently applied pre-determined eligibility criteria and extracted data on cause-specific cancer deaths, overall mortality and the occurrence of metastatic spread. Meta-analyses were then conducted for different cancers and heterogeneity and publication bias assessed. Sensitivity analyses and attempts to reduce heterogeneity were conducted. RESULTS: Analyses of 29 studies reported since an earlier review up to April 2015 are presented in this report, and these are then pooled with the 42 studies in our earlier publication. Overall meta-analyses of the 71 studies are presented, based on a total of over 120 thousand patients taking aspirin. Ten of the studies also give evidence on the incidence of metastatic cancer spread. There are now twenty-nine observational studies describing colorectal cancer (CRC) and post-diagnostic aspirin. Pooling the estimates of reduction by aspirin which are reported as hazard ratios (HR), gives an overall HR for aspirin and CRC mortality 0.72 (95% CI 0.64-0.80). Fourteen observational studies have reported on aspirin and breast cancer mortality and pooling those that report the association with aspirin as a hazard ratio gives HR 0.69 (0.53-0.90). Sixteen studies report on aspirin and prostate cancer mortality and a pooled estimate yields an HR of 0.87 (95% CI 0.73-1.05). Data from 12 reports relating to other cancers are also listed. Ten studies give evidence of a reduction in metastatic spread; four give a pooled HR 0.31 (95% CI 0.18, 0.54) and five studies which reported odds ratio of metastatic spread give OR 0.79 (0.66 to 0.95). CONCLUSION: Being almost entirely from observational studies, the evidence of benefit from aspirin is limited. There is heterogeneity between studies and the results are subject to important biases, only some of which can be identified. Nevertheless, the evidence would seem to merit wide discussion regarding whether or not it is adequate to justify the recommendation of low-dose therapeutic aspirin, and if it is, for which cancers?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984 · cited 2×
“Some of the long-term follow-up studies of early vascular trials gave evidence of reductions attributable to aspirin in the metastatic spread of a range of cancers in subjects who had been free of metastases at diagnosis [11] again suggesting a treatment effect of aspirin.”
BackgroundRothwell, P. M., Price, J. F., Fowkes, F. G. R., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61720-0 · Cited by 839 · cited 3×
“The role of low-dose aspirin prophylaxis is well established in vascular disease [1,2] and in the reduction of colorectal, and probably other cancers [3±5], and it has been predicted that that `preventionof cancer could become the main justification for aspirin use' [6].”
BackgroundThe Hypercoagulable State of Malignancy: Pathogenesis and Current Debate
Caine, G. J., Stonelake, P. S., Lip, G. Y. H., & Kehoe, S. T. (2002) · Neoplasia · doi:10.1038/sj.neo.7900263 · Cited by 576
Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism
Brighton, T. A., Eikelboom, J. W., Mann, K., Mister, R., Gallus, A., Ockelford, P., Gibbs, H., Hague, W., Xavier, D., Diaz, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210384 · Cited by 563
Incorporating Patients' Preferences into Medical Decisions
Kassirer, J. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302611 · Cited by 415 · cited 1×
“Because of the various uncertainties, the adequate informing of patients of the benefits and the harm is difficult, but it is important that shared decision making is not compromised by `intrusiveexternal decisions' [90].”
BackgroundRothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31133-4 · Cited by 353
Cited by
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
Repurposing quinacrine for treatment-refractory cancer
Oien, D. B., Pathoulas, C. L., Ray, U., Thirusangu, P., Kalogera, E., & Shridhar, V. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.021 · Cited by 87
Chuang, M.-C., Yang, Y.-H., Hsieh, M.-J., Lin, Y.-C., Yang, T.-M., Chen, P.-C., & Hung, M.-S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08999-8 · Cited by 9
Metadata
- Authors
- Elwood, P. C., Pickering, J. E., Morgan, G., Galante, J., Weightman, A. L., Morris, D., Longley, M., Mason, M., Adams, R., Dolwani, S., Chia W. K., J., & Lanas, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-09-25
- Volume
- 13
- Issue
- 9
- Pages
- e0203957
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2893325913
- Cited by
- 43
- References
- 7
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients? https://app.cochat.ai/papers/10.1371/journal.pone.0203957
- The paper
- Elwood, P. C., Pickering, J. E., Morgan, G., Galante, J., Weightman, A. L., Morris, D., Longley, M., Mason, M., Adams, R., Dolwani, S., Chia W. K., J., & Lanas, A. (2018). Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients? PLOS ONE. https://doi.org/10.1371/journal.pone.0203957
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.